BOSTON: PureTech Health plc, an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, announced a new corporate headquarters and labs in Boston’s Seaport District. [the_ad id=”31605″]The state-of-the-art, integrated office and laboratory space will support the Company’s plans to expand and accelerate development of its internal R&D pipeline, which is centred on lymphatic targeting and tissue-selective immunomodulation for the potential treatment of immune and central nervous system disorders, lymphatic conditions, and cancers.
“The PureTech team has initiated and advanced highly differentiated product candidates initially targeting serious disorders of the brain, immune system, and gastrointestinal tract, and has progressed more than two dozen product candidates from discovery through various points of validation, including one all the way through FDA regulatory clearance. It is through this track record of execution that we have built our leadership position around brain-immune-gut “BIG” axis biology and identified the platforms that form the basis of our internal R&D pipeline programs,” said founder and CEO Daphne Zohar.
“PureTech’s expanded presence in the world’s premier biotech and biopharmaceutical R&D ecosystem reflects our commitment to leveraging this unique expertise around the BIG axis with the goal of bringing transformational new medicines to patients.”